Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/3220
Título : In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm
Autor : Artigas, Laura
Coma, Mireia
Matos-Filipe, Pedro
Aguirre-Plans, Joaquim
Farrés, Judith
Valls, Raquel
Fernandez-Fuentes, Narcis
de la Haba-Rodriguez, Juan
Olvera, Alex
Barbera, Jose
Morales, Rafael
Oliva, Baldo
Mas, Jose Manuel
Filiación: [Artigas,L; Coma,M; Matos-Filipe,P; Farrés,J; Valls,R; Mas,JM] Anaxomics Biotech, Barcelona, Spain. [Matos-Filipe,P; Aguirre-Plans,J; Oliva,B] Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Department of Experimental and Health Science, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain. [Fernandez-Fuentes,N] Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia, Spain. [de la Haba-Rodriguez,J] Maimonides Biomedical Research Institute, Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. [Olvera,A] Institut de Recerca de la Sida-IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain. [Barbera,J; Morales,R] Servicio de Medicina interna-Unidad de Infecciosas, La Mancha-Centro Hospital, Alcázar de San Juan, Spain.
Palabras clave : Coronavirus infections
Infecciones por coronavirus
Antiviral agents
Melatonin
Combined modality therapy
Antivirales
Melatonina
Terapia combinada
MeSH: Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents
Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Melatonin
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Drug Discovery::Drug Repositioning
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridines::Pyridones
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Proprotein Convertases::Furin
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Information Science::Information Science::Medical Informatics::Medical Informatics Applications::Information Systems::Databases as Topic::Databases, Factual::Databases, Pharmaceutical
Fecha de publicación : 2-Oct-2020
Editorial : PLOS
Cita Bibliográfica: Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farrés J, Valls R. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One. 2020 Oct 2;15(10):e0240149.
Abstract: From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications.
URI: http://hdl.handle.net/10668/3220
Versión del editor : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0240149
DOI: 10.1371/journal.pone.0240149
ISSN : 1932-6203 (Online)
Appears in Collections:01- Artículos - IMIBIC. Instituto Maimónides de Investigación Biomédica de Córdoba
01- Artículos - Hospital Reina Sofía

Files in This Item:
File Description SizeFormat 
Artigas_InsilicoDrug.pdfArtículo publicado2 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons